Oxidative stress in HIV-1-infected injection drug users.
Low serum antioxidant levels observed in many HIV-infected populations could be largely due to an increase in oxidative stress (defined as a disturbance in the equilibrium status of prooxidant/antioxidant systems of intact cells). In HIV infection, oxidative stress may be caused by both overproduction of reactive oxygen intermediates (ROIs) and a simultaneous deficiency of antioxidant defenses. Furthermore, injection drug use has been associated with increased levels of oxidative stress in animal models. Currently, there is widespread use of self-prescribed antioxidant supplementation among the HIV-infected population and a prevailing belief that high-dose supplementation is beneficial, or at the very least, not harmful. Data from our studies show that HIV-positive injection drug users (IDUs) who are on antiretroviral combination therapies including a protease inhibitor have significantly higher mean serum levels of several antioxidants, independent of dietary and supplemental intake, compared with both HIV-negative IDUs and HIV-positive IDUs not taking protease inhibitors. This suggests that oxidative stress may be reduced in patients taking protease inhibitors. Preliminary data suggest that the future of antioxidant supplementation therapy, if any, will be one in which different doses of supplements are recommended for HIV-infected patients on the various antiretroviral treatment regimens. More research is needed to determine the interactions among injection drug use, oxidative stress, antiretroviral therapy, and the use of antioxidant supplements in HIV infection. Until more is known, caution should be exercised when using or recommending high-dose antioxidant supplementation in HIV-infected individuals, particularly in those on protease inhibitors, since moderate levels of oxidative stress are involved in a number of useful physiologic processes.
Tang
A M
AM
Department of Family Medicine and Community Health, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Smit
E
E
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000821:virology; D015497:HIV-1; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000378:metabolism
D019380:Anti-HIV Agents; D000975:Antioxidants